Our Milestones & Accomplishments
Published pre-clinical studies validating vaccine platform
Created proprietary database of all human and pet mRNA-derived neoantigens (REDNs)
Validated diagnostic sensitivity and specificity for stage 1 tumor detection on our Diagnostic chips
Completed 800+ dog 5 year trial showing safety and efficacy of our vaccine
Collected largest bank of blood from pets with
stage 1 tumors
Developed a process for functionally screening for immunogenic, shared neoantigens on our Discovery chips
Established scalable manufacturing of Diagnostic chips
Business Plan & Product Timeline
Calviri will produce the dog diagnostics and vaccines, then use the data and revenues to transition to production of human versions. Diagnostics will be licensed to strategics for commercialization, the vaccines will be retained and commercialized internally by Calviri.
Our Cancer Products
​Early Diagnostics:
Early Detection: We have invented universal, peptide diagnostic chips that solve the sensitivity problem for detecting most stage 1 cancers, using a single test. It accurately measures tumor-specific antibody responses in a small amount of blood.
Therapeutic Vaccines:
Vaccines to Treat: We have discovered a unique, rich source of immunogenic, shared tumor neoantigens that provides components for off-the-shelf therapeutic vaccines. These will serve as companion products to our early diagnostic tests.
Preventative Vaccines
Vaccines to Prevent: The same rich source of immunogenic neoantigens that are shared among tumors, even very different tumor types, provides components for off-the-shelf preventative vaccines. Instead of treating early cancer, these vaccines will prevent early cancer.
Presentations, Webinars & Events
Calviri’s insights and innovations allow us to make diagnostics and vaccines that have already shown the potential to enormously impact health, globally. These products are all based on our unique neoantigens and chips; they are the key. Our canine preventative cancer vaccine is working. The data demonstrating our diagnostic capabilities will drive partnership and licensing negotiations for the dog diagnostic tests. Calviri’s neoantigens and chips make ending cancer possible.
Previous Presentations & Events
2024
BIO International (June)
AACR Partnering (April)
Venture Café Phoenix (April)
Phoestival of Health-PBC (April)
Cancer at the Crossroads (March)
2023
MedInvest Oncology Investor Conference
World Vaccine Congress West Coast
Genetic Predisposition to Primary CNS Cancer
Venture Care
Senate Health Committee-State Capital
Preventive Cancer Vaccine
Event
​
Spotlight on Cancer Early Detection
Cancer Prevention​​
​
Event
Calviri aims to end cancer worldwide with a diagnostic to detect cancer early and vaccines to treat or even pervent cancer
Demonstration of a Universal Preventative Cancer Vaccine
​
A Vaccine Strategy to Prevent Cancer
​
Preventing Cancer Might Be Easier Than Most Think
​
Our work to end cancer and connection to ASU
Vaccine Data for USDA
USDA
2022
World Vaccine & Immonotherapy Summit
Vaccine Summit Washington, DC
Next Generation Cancer Vaccine Development Summit
NCI Animal Model Workshop
A new approach to therapeutic cancer vaccines; A novel platform for early diagnosis & predicting responses to immune checkpoint inhibitor treatment
A New Source of Cancer NeoAntigens as the Basis for a Broadly Preventative Cancer Vaccine
​
The case for creating a broadly protective preventative cancer vaccine: Report on a large canine clinical Trial Testing the concept; A simple blood-based assay to predict response to immunotherapy and immune related adverse events
​
Animal Models for Cancer
2020
World Vaccine Congress
JP Morgan
RNA Frameshift Errors Provide New Vaccine Product Opportunities Against Cancer
Ending Death from Cancer - Calviri presents investment opportunity
2019
Arizona Bioindustry Association
Midwestern University
Molecular Med Tri-Con
Molecular Med Tri-Con
PepTalk
Going to the Dogs – How the Largest Canine Clinical Trial in History May Lead to New Hope for Humans
Shifting the paradigm in diagnosing and treating cancer
RNA generated frameshift neoantigens in tumors are useful in diagnosis and vaccination
Using a blood-based 400K frameshift peptide array to develop cancer type-specific vaccinations
A new source of neoantigens and a platform for their discovery
2018
Molecular Med Tri-Con
Immune Oncology Summit
American College of Veterinary Internal Medicine
Golden Retriever Club of America
United States Patent and Trademark Office
European NeoAG Summit
Cancer type specific FAST vaccines based on frameshift neoantigens
Tapping a new source of neoantigens: applications in therapy and diagnostics
A new blood based approach to early diagnosis of cancer
Calviri’s Technology Enables a Universal Preventative Vaccine
Inventions to effectively eradicate cancer
Shifting the paradigm in diagnosing and treating cancer
2018
Golden Retriever Club of America
An alternative source of neoantigens offers new approaches to personal and general vaccines
Contact Us
Please direct any questions or comments you have for us via our contact form below.
